{"filings":[{"id":1038997,"accession_number":"0001636282-26-000083","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-06-15T12:01:32+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spyre reports positive Phase 2 topline data for SPY002 in ulcerative colitis; met primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY002 achieved primary endpoint: 10.7-point RHI reduction (p<0.0001) at 12 weeks.","Clinical remission rate 33%, endoscopic improvement rate 42%, modified Mayo Score change -3.7.","Well tolerated; safety profile consistent with TL1A class; no drug-related SAEs.","Two SAEs (UC exacerbation, heart failure) deemed not drug-related; no deaths.","Company on track to report SPY003 Part A data in Q3 2026 and enrolling Part B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":777718,"accession_number":"0001636282-26-000075","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-06-01T20:01:39+00:00","items":["8.01","9.01"],"status":"ready","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["License field expanded from inflammatory bowel disease to all human disease indications.","Monotherapy dosing for non-IBD indications restricted until June 1, 2030; combination until June 1, 2028.","Restrictions may terminate earlier upon a Material Transaction (change of control, asset sale) by June 1, 2028.","Paragon receives non-exclusive license under Spyre's cross-license patents for retained IL-23 antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748117,"accession_number":"0001636282-26-000056","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-05-29T20:45:58+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amended and restated 2016 ESPP (66.9M for, 45.5K against) at May 27 annual meeting.","Director Peter Harwin resigned effective May 27, 2026; Board reduced from 8 to 7 directors.","Elected Class I directors Mark McKenna, Cameron Turtle, and Laurie Stelzer to 2029 term.","Non-binding advisory vote on executive compensation passed with 62.1M for, 4.8M against.","Ratification of KPMG as independent auditor for FY2026 passed with 68.4M for, 670 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94272,"accession_number":"0001636282-26-000051","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).","Pro forma cash $1,176.8M as of March 31, 2026, including $435.3M net from April 2026 offering; runway into H2 2029.","SPY001 achieved primary endpoint in Part A of SKYLINE: RHI score reduction 9.2 points (p<0.0001); clinical remission 40%, endoscopic improvement 51%.","SPY001 safety consistent with α4β7 class; RA sub-study of SKYWAY over-enrolled, topline readout accelerated to Q3 2026.","On track for 6 proof-of-concept readouts in 2026 across SKYLINE and SKYWAY Phase 2 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94271,"accession_number":"0001628280-26-025508","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Spyre Therapeutics raises ~$463.5M in underwritten public offering of 7.475M shares at $62.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$463.5M from 7.475M shares including full exercise of over-allotment option at $62.00/share.","Proceeds to fund IBD and rheumatic disease programs, including preclinical, clinical trials, manufacturing, and Phase 3 readiness.","Underwriting agreement with Jefferies, Goldman Sachs, Evercore, and Guggenheim Securities as representatives.","Offering closed on April 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94270,"accession_number":"0001628280-26-024906","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Spyre reports preliminary $741M cash; suspends ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.","Includes $30M legacy asset disposition proceeds; $23M expected to be paid to CVR holders in Q2 2026.","Effective April 13, 2026, terminated ATM prospectus; no further share sales under Sales Agreement until new filing.","Sales Agreement with TD Securities remains in force; company funded without current need for dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94269,"accession_number":"0001628280-26-024831","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spyre SPY001 meets primary endpoint in Phase 2 SKYLINE Part A for UC; 40% clinical remission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY001 achieved primary endpoint with RHI reduction of 9.2 points (p<0.0001) at Week 12.","Secondary endpoints: clinical remission 40%, endoscopic improvement 51%, Modified Mayo Score change -3.7.","Well tolerated: 6 TEAEs (14%), 1 SAE deemed not drug-related; no drug-related AEs or discontinuations.","Part A enrollment closed; Part B enrolling monotherapy (SPY001/002/003) and combination cohorts.","Proof-of-concept data expected mid-2026 for SPY002, Q3 2026 for SPY003; Part B data on track for 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106501,"accession_number":"0001636282-26-000022","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Therapeutics reports Q4 2025 net loss of $62.5M; cash $756.5M; Phase 2 readouts expected Q2/Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $62.5M (vs $56.3M Q4 2024); R&D expense $44.6M (vs $50.5M).","Cash, cash equivalents, and marketable securities $756.5M at Dec 31, 2025; raised $316.2M gross in Oct 2025 public offering.","On track for 6 proof-of-concept readouts in 2026: SKYLINE Part A (IBD) data expected Q2 2026; SKYWAY trial (RA, PsA, axSpA) data expected Q4 2026.","Appointed Kate Tansey Chevlen as Chief Commercial Officer.","Expected cash runway into second half of 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106500,"accession_number":"0001193125-26-009894","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.","SPY001 enrollment complete ahead of schedule; SKYLINE Part A readouts now expected to begin Q2 2026.","Six total proof-of-concept readouts planned: 3 from SKYLINE (UC) and 3 from SKYWAY (RA, PsA, axSpA) by 4Q 2026.","Pro forma cash $783M as of Sept 30, 2025, including Oct 2025 offering net proceeds; runway into H2 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122845,"accession_number":"0001636282-25-000104","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.","SPY003 well tolerated, no serious adverse events; safety profile consistent with anti-IL-23 class.","Q3 2025 net loss of $11.2M, compared to $69.0M in Q3 2024; R&D expenses $45.2M.","Pro forma cash $782.7M as of Sep 30, 2025, including $296.5M net from October 2025 public offering.","Company expects 6 proof-of-concept readouts in 2026 from SKYLINE and SKYWAY Phase 2 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122844,"accession_number":"0001193125-25-240237","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.","Gross proceeds of approximately $316.2 million before underwriting discounts and expenses.","Net proceeds to fund IBD and rheumatic disease programs, including clinical trials and Phase 3 readiness.","Underwriters include Jefferies, TD Securities, Leerink Partners, and Stifel; offering closed Oct 15, 2025.","Offering was made under existing effective shelf registration statement (File No. 333-285341)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122843,"accession_number":"0001193125-25-237904","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Spyre Therapeutics expects $486.2M cash as of Sept 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of ~$486.2M as of Sept 30, 2025.","Full Q3 2025 financial results not yet finalized; subject to completion of closing procedures.","Company cautions that final amount may differ materially from preliminary estimate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139547,"accession_number":"0001636282-25-000091","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Q2 net loss $36.7M; cash $526.6M; initiates Phase 2 SKYLINE-UC; TL1A data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.7M for Q2 2025 ($38.8M in Q2 2024); stock-based compensation $9.4M.","Cash, equivalents, and marketable securities of $526.6M as of June 30, 2025; expected runway into H2 2028.","R&D expense rose to $40.1M from $32.6M YoY on higher clinical trial costs; recognized $10.0M gain on sale of legacy asset pegzilarginase.","Positive interim Phase 1 data for two anti-TL1A antibodies (SPY002/SPY072): well-tolerated, PK supports Q3M/Q6M dosing, full TL1A engagement to 20 weeks.","Initiated Phase 2 SKYLINE-UC platform in May; on track to start Phase 2 SKYWAY-RD basket study in Q3 2025; SPY003 Phase 1 data expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157119,"accession_number":"0001193125-25-141756","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.","SPY002 half-life ~75 days (≥3x first-gen anti-TL1As); supports quarterly or twice-yearly SC dosing.","Single 100 mg dose of either antibody suppressed free TL1A below LLOQ through 20 weeks.","SKYLINE-UC (UC) platform trial started May 2025; SKYWAY-RD basket (RA, PsA, axSpA) planned Q3 2025.","Expects 9 Phase 2 readouts by 2027; cash runway into H2 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157118,"accession_number":"0001636282-25-000063","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.","Advisory vote on executive compensation approved: 42.9M for, 3.1M against, 0.1M abstain, 3.1M broker non-votes.","Ratified KPMG LLP as independent auditor for FY2025: 49.2M for, 57k against, 9k abstain, no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157117,"accession_number":"0001636282-25-000050","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Therapeutics Q1 net loss $44.8M; cash $564.8M; on track for Phase 2 starts mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities of $564.8M as of March 31, 2025.","Net loss of $44.8M for Q1 2025 vs. $43.9M in Q1 2024; R&D expenses rose to $41.6M.","Extended Phase 1 data for SPY001 supports potential quarterly or biannual dosing; Phase 2 initiation planned mid-2025.","Interim Phase 1 data for SPY002 expected Q2 2025; first participant dosed in Phase 1 trial of SPY003.","Plan to initiate Phase 2 trials in UC and RA mid-2025 with 7+ proof-of-concept readouts in 2026-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175480,"accession_number":"0001193125-25-048423","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Spyre dismisses PwC as auditor, appoints KPMG; discloses material weakness in controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PwC dismissed as auditor effective Feb 28, 2025; KPMG appointed as new independent auditor for FY2025.","No disagreements with PwC on accounting principles; material weakness identified as of Dec 31, 2024 in controls over EPS calculation for convertible preferred stock.","Material weakness led to restatement of FY2023 consolidated financial statements.","PwC's reports for FY2024 and FY2023 were unqualified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175479,"accession_number":"0001636282-25-000022","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.","Raised $230M in November 2024 public offering; Q4 net cash used in operations $37.2M.","Interim Phase 1 data for SPY001 (α4β7) shows half-life >90 days supporting Q6M dosing; Phase 2 UC trial mid-2025.","SPY002 (TL1A) Phase 1 interim data expected Q2 2025; Phase 2 RA trial initiation mid-2025; top-line 2026.","SPY003 (IL-23) FIH trial starts Q1 2025 with interim data H2 2025; Phase 2 platform trial mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175478,"accession_number":"0001193125-25-005015","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.","Phase 1 interim data for SPY002 (TL1A) expected 2Q2025; SPY003 (IL-23) Phase 1 interim data in 2H2025.","Phase 2 platform trial in UC launching mid-2025 with SPY001, SPY002, SPY003, and combinations; initial open-label data mid-2026.","SPY002 expansion into rheumatoid arthritis; Phase 2 RA trial start mid-2025 with topline results in 2026.","SPY001 Phase 1 data showed half-life >90 days, supporting quarterly to twice-annual subcutaneous dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192437,"accession_number":"0001628280-24-048527","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.","Gross proceeds expected to be approximately $200M before expenses; net proceeds plus existing cash expected to fund operations into H2 2028.","Underwriters: Jefferies, Goldman Sachs, Evercore, Guggenheim; closing expected Nov 20, 2024.","Offered pursuant to Form S-3 shelf registration; prospectus supplement filed Nov 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192436,"accession_number":"0001636282-24-000105","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["4.02","8.01"],"status":"ready","headline":"Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restating audited and unaudited financials from Dec 31, 2023 to Sep 30, 2024 due to misapplication of GAAP in EPS calculation for preferred stock.","Common stock net loss per share changed for all affected periods; e.g., Q3 2024 revised from ($1.36) to ($1.06).","Series A Preferred stock EPS restated (e.g., Q3 2024: ($42.22) vs. not previously reported).","Material weakness in internal controls over financial reporting identified; remediation plan to be filed.","No impact on cash position or other financial data; amendments to prior filings expected soon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192435,"accession_number":"0001628280-24-046860","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.","No serious adverse events; all adverse events mild; no Grade 2+ TEAEs; no trial discontinuations.","Complete α4β7 receptor saturation maintained through Day 57 with single 300mg dose.","Phase 2 UC platform trial expected to start mid-2025; ~500 subjects, 12-week induction + 38-week maintenance.","Portfolio maintenance dosing guidance updated to Q3M-Q6M for monotherapies and combinations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192434,"accession_number":"0001636282-24-000085","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.","Cash, cash equivalents and marketable securities of $414.2M as of Sep 30, 2024; runway extended well into 2027.","SPY001 Phase 1 interim data expected by year-end 2024; SPY002 FIH trials initiated in Q4 2024.","Appointed Sheldon Sloan, M.D., as Chief Medical Officer, effective October 2024.","Preclinical data for SPY003 at UEGW showed >3-fold half-life extension vs risankizumab; FIH accelerated to Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192433,"accession_number":"0001193125-24-237150","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.","Preclinical data at UEGW shows comparable potency to risankizumab with >3x half-life extension in NHPs (~30 days).","Licensed IL-23 antibodies from Paragon for up to $22M in development/regulatory milestones plus low single-digit royalties.","Portfolio includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.","Combination data shows synergy of anti-IL-23 with anti-TL1A or anti-α4β7 in reducing IL-17 and inflammation in models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208903,"accession_number":"0001636282-24-000058","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K/A","filed_at":"2024-08-08T23:59:59+00:00","items":[],"status":"ready","headline":"Spyre Therapeutics files 8-K/A to correct date on cover page of prior filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Amendment corrects clerical error on cover page date of Original 8-K filed August 7, 2024.","No changes to financial results, disclosures, or exhibits from the original report.","Original 8-K reported Q2 2024 financials; this filing only revises the report date.","No new material information for investors; purely administrative correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208904,"accession_number":"0001636282-24-000053","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.","R&D expenses increased to $32.6M (vs $17.4M) driven by IBD pipeline advancement; no acquired IPR&D in Q2 2024.","SPY001 (anti-α4β7) Phase 1 dosing initiated; interim proof-of-concept data expected by end of 2024 for every-8-12 week dosing.","SPY002 (anti-TL1A) two candidates with subnanomolar potency; FIH trials in H2 2024 with interim data in H1 2025.","SPY003 (anti-IL-23) development candidate nominated; FIH trial expected in H1 2025; $426M cash runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226710,"accession_number":"0001193125-24-150395","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Spyre Therapeutics updates share count: 50.8M actual, 65.3M pro forma","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["As of May 29, 2024, common shares outstanding: 50,782,384.","Pro forma shares (incl. Series A & B preferred conversion): ~65.3 million.","Conversion of Series B Preferred was effective per prior 8-K filed May 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226709,"accession_number":"0001193125-24-138893","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["1.01","5.02","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Spyre licenses Paragon’s α4ß7 and TL1A antibodies, appoints Dr. Milligan to board, and approves Series B conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered exclusive license with Paragon for α4ß7 and TL1A antibodies; up to $22M milestones per program plus low single-digit royalties.","Appointed Dr. Sandra Milligan (former Merck, Genentech, Amgen executive) to Board of Directors, effective May 14, 2024.","Stockholders approved issuance of common upon conversion of Series B Preferred (Dec 2023 and Mar 2024 tranches).","Pro forma shares outstanding expected ~65.2M after full conversion of Series B and Series A Preferred.","Certificate of Amendment extended officer exculpation provisions in charter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226708,"accession_number":"0001636282-24-000039","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre reports Q1 net loss $43.9M; cash $485M; SPY001 on track for FIH Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $43.9M for Q1 2024, including $13.8M non-cash stock comp; vs $18.4M loss in Q1 2023.","Cash, equivalents, marketable securities, and restricted cash total $485M as of March 31, 2024.","Raised $180M in March 2024 private placement; expected runway into 2027 through clinical readouts.","SPY001 (anti-α4β7) cleared 28-day GLP tox; FIH study to start Q2 2024 with interim data expected year-end 2024.","SPY002 (anti-TL1A) on track for FIH in H2 2024; SPY003 (anti-IL-23 p19) candidate nomination set for mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226707,"accession_number":"0001193125-24-113954","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Spyre exchanges 90,992 Series A Preferred shares for 3.64M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["90,992 shares of Series A Non-Voting Convertible Preferred Stock exchanged for 3,639,680 shares of common stock.","Exchange closed April 25, 2024; common shares outstanding post-exchange: 40,279,414.","Exemption from registration relied on Section 3(a)(9) of Securities Act; no commission paid.","Counterparty is Fairmount Healthcare Fund II L.P.; conversion ratio based on existing conversion terms.","Following exchange, 346,045 Series A Preferred and 271,625 Series B Preferred remain outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245672,"accession_number":"0001193125-24-069693","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["1.01","5.03","3.02","7.01","9.01"],"status":"ready","headline":"Spyre Therapeutics announces $180M private placement of convertible preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spyre raises ~$180M via PIPE: 121,625 Series B convertible preferred shares at $1,480 each.","Series B convertible into 4,865,000 common shares (40:1), subject to stockholder approval and beneficial ownership limits.","PIPE includes new and existing investors; expected close on March 20, 2024.","Proceeds to fund pipeline programs and extend cash runway well into 2027.","Authorized Series B shares increased from 150,000 to 271,625 via Certificate of Amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245671,"accession_number":"0001636282-24-000007","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Q4 2023 net loss $63.2M; cash $339.6M; pipeline on track with SPY001 FIH H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.2M in Q4 2023 vs $18.8M in Q4 2022; cash $339.6M as of Dec 31, 2023.","Raised $180M gross from private placement; cash runway into H2 2026.","SPY001 anti-α4β7 shows 22-day half-life (3x vedolizumab); FIH studies expected H1 2024 with interim data year-end.","SPY002 anti-TL1A candidates nominated; preclinical half-life 24 days (2-3x clinical-stage); FIH in H2 2024.","Appointed CEO Cameron Turtle and board member Mark McKenna; name changed to Spyre Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":-49.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":886000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245670,"accession_number":"0001193125-24-023462","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["1.01","5.02","5.03","5.05","9.01"],"status":"ready","headline":"Spyre appoints Mark McKenna as director; CEO severance amended","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alison Lawton resigned from Board effective Feb 1, 2024; no disagreement cited.","Mark McKenna appointed Class I director; former CEO of Prometheus Biosciences (acquired by Merck).","CEO Cameron Turtle's severance increased by 0.5x target bonus in change-in-control event.","McKenna granted option for 40,000 shares under equity plan; consulting agreement grants 477,000 options.","Board adopted amended bylaws, new code of conduct, and indemnification agreements for directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245669,"accession_number":"0001193125-24-010226","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Spyre Therapeutics transfers listing to Nasdaq Global Select Market effective Jan 19, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received approval from Nasdaq to transfer listing from Capital Market to Global Select Market.","Effective at the opening of business on January 19, 2024.","Common stock continues to trade under the symbol SYRE.","Transfer indicates the company met stricter financial requirements for higher-tier market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263140,"accession_number":"0001193125-23-291257","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["1.01","5.03","3.02","7.01","9.01"],"status":"ready","headline":"Spyre raises $180M PIPE via 6M common shares at $15 and 150K Series B convertible preferred","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["6,000,000 common shares at $15/share and 150,000 Series B preferred shares at $600/share (convertible into 40 common each).","Gross proceeds ~$180M; closing expected Dec 11, 2023; net proceeds to fund pipeline and extend cash runway into H2 2026.","Investor group includes Access Biotechnology, Venrock, Perceptive Advisors, RTW Investments, Braidwell, Fairmount, Cormorant, Polar Capital, Boxer Capital, Deep Track Capital, and others.","Jefferies, TD Cowen, Stifel, Guggenheim, and LifeSci Capital acted as joint placement agents.","Series B preferred is non-voting; converts automatically upon stockholder approval, subject to 19.9% beneficial ownership cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263139,"accession_number":"0001193125-23-283693","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Spyre Therapeutics appoints Cameron Turtle CEO; name change to Spyre, ticker SYRE effective Nov 28","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cameron Turtle, previously COO, appointed CEO and director; $625K base, 55% target bonus, option for 374K shares at $10.39.","Name change from Aeglea BioTherapeutics to Spyre Therapeutics; ticker changes from AGLE to SYRE effective Nov 28, 2023.","Directors Ivana Magovčević-Liebisch and Hunter Smith resign; Laurie Stelzer (chair audit) and Jeffrey Albers appointed to board.","Pipeline on track: SPY001 (anti-α4β7) FIH H1 2024; SPY002 (anti-TL1A) FIH H2 2024; SPY003 (anti-IL-23) IND 2025; cash $205M into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263138,"accession_number":"0001193125-23-282424","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["5.03","5.07","7.01","9.01"],"status":"ready","headline":"Aeglea shareholders approve increase in authorized shares to 400M and preferred conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 20M to 400M via Certificate of Amendment.","Stockholders approved issuance of up to 43.45M shares upon conversion of Series A Preferred Stock.","Amendment and restatement of 2016 Equity Incentive Plan approved.","Pro forma shares outstanding ~47.8M after full Series A conversion and pre-funded warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263137,"accession_number":"0001193125-23-277985","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aeglea recasts FY2022 financials for 1-for-25 reverse split; going concern warning persists","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-25 reverse stock split effective Sept 8, 2023; authorized shares cut from 500M to 20M.","Recast FY2022 net loss $83.8M ($24.86/share) on total revenue of $2.3M.","Accumulated deficit $425.6M as of Dec 31, 2022; cash & securities $57.3M.","Substantial doubt about going concern; cash expected to fund only into Q4 2023.","Auditor's opinion includes going concern emphasis paragraph."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263136,"accession_number":"0001636282-23-000016","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aeglea BioTherapeutics Q3 2023 net loss $40.1M; cash $204.9M; IBD pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.1M in Q3 2023 vs $18.2M a year ago, reflecting $24.7M R&D (+106% YoY) and $21.8M other expense.","Cash, equivalents, marketable securities and restricted cash $204.9M at Sept 30, 2023, expected runway into 2026.","SPY001 anti-α4β7 IND expected H1 2024; healthy volunteer interim data year-end 2024.","SPY002 anti-TL1A IND expected H2 2024; picomolar affinity for monomer/trimer cited.","Stockholder vote Nov 21 to authorize preferred-to-common conversion; sold pegzilarginase to Immedica for $15M upfront plus milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-69.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":886000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263135,"accession_number":"0001193125-23-261221","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aeglea BioTherapeutics posts corporate presentation showing anti-TL1A antibody SPY002 with picomolar potency","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Non-clinical data for SPY002 (anti-TL1A antibody) show monomer and trimer binding at picomolar potencies.","Corporate presentation posted on October 24, 2023, includes updates on research pipeline.","No new financial results, guidance, or material operational changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263134,"accession_number":"0001193125-23-252523","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Aeglea appoints Cameron Turtle as PEO; discloses substantial doubt about going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cameron Turtle appointed principal executive officer effective Oct 6, 2023; previously COO since June 2023.","Company received SEC waiver to file abbreviated financials for Spyre acquisition; net liabilities assumed of $17.0M.","Substantial doubt about going concern if stockholders do not timely approve Series A Preferred Stock conversion.","As of June 22, 2023, Spyre had cash $3.0M and accrued liabilities $20.0M; total acquisition cost was $113.2M.","Company reduced workforce by 83% in April 2023 to ~10 employees; exploring strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263133,"accession_number":"0001193125-23-251664","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aeglea amends Paragon agreement, commits to annual 1% option grants for 2023-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual option grant of 1% of outstanding Aeglea common stock (fully-diluted) to Parapyre for calendar years 2023 and 2024.","Grant date set to last business day of each applicable year; options vest immediately and have a 10-year term.","Paragon and Parapyre each hold less than 5% of Aeglea's capital stock; Fairmount (>5% holder) controls Paragon's board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280356,"accession_number":"0001193125-23-241316","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["1.01","3.01","5.02","9.01"],"status":"ready","headline":"Aeglea regains Nasdaq compliance, enters WuXi Biologics deals, details CFO separation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained Nasdaq minimum bid price compliance after 1-for-25 reverse stock split effective Sept 8, 2023.","Novated WuXi Biologics MSA for SPY001 program; term through June 2027 or completion of work orders.","Entered cell line license agreement with WuXi Biologics; $150k license fee plus potential single-digit royalty on third-party manufactured sales.","Former CFO Jonathan Alspaugh severance: $623k cash, $168k retention bonus, $500/hr consulting fee through Feb 2024, and accelerated option vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280355,"accession_number":"0001193125-23-231646","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["3.03","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Aeglea Biotherapeutics effects 1-for-25 reverse stock split and reduces authorized shares to 20M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-25 ratio effective Sept 8, 2023; no fractional shares issued; cash in lieu.","Authorized common shares reduced from 500M to 20M.","Proportional adjustments to Series A preferred conversion, outstanding warrants, and equity awards.","Corporate presentation: adjusted total capitalization ~47.7M shares as-converted as of June 22, 2023.","2022 net loss per share restated to $(24.86) on weighted-average shares of 3.37M post-split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280354,"accession_number":"0001193125-23-228076","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Aeglea appoints Scott Burrows as CFO, Heidy Abreu King-Jones as CLO; prior CFO transitions to advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Burrows appointed CFO effective Sept 1, 2023, succeeding Jonathan Alspaugh; base salary $455K, target bonus 40%, sign-on $115K.","Heidy Abreu King-Jones appointed Chief Legal Officer & Corporate Secretary; both report to COO Cameron Turtle.","Jonathan Alspaugh transitions to strategic advisory role through Dec 31, 2023; he was President and CFO.","Burrows received inducement options for 10,121,441 shares and 3,373,814 RSUs; King-Jones options for 13,495,255 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280353,"accession_number":"0001193125-23-209727","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Aeglea BioTherapeutics terminates Austin office lease, pays $2M termination fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated lease for Suites 100, 110, and 150 at 805 Las Cimas Parkway, Austin, TX effective Aug 8, 2023.","Lease originally dated April 30, 2019, amended Oct 2019 and Jan 2020; terminated via agreement with Landlord Las Cimas Owner LP.","Company paid a termination fee of $2 million as consideration for release from all future obligations under the lease.","No further obligations to Landlord arise or accrue from and after the Termination Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280352,"accession_number":"0000950170-23-041586","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aeglea closes Spyre asset acquisition, raises $210M, sells pegzilarginase, reports Q2 loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired Spyre's IBD pipeline (α4β7 and TL1A) for stock; raised $210M gross via Series A preferred private placement.","Sold pegzilarginase rights to Immedica for $15M upfront + up to $100M milestones; net proceeds to CVR holders.","Cash and equivalents $236.7M at June 30, including $210M financing; Q2 net loss $217.1M from acquisition-related charges.","Net loss includes $130.5M acquired IPR&D expense and $58.2M forward contract liability expense.","Expect SPY001 FIH study in H1 2024; SPY002 FIH study in H2 2024; healthy volunteer data by end-2024 / H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280351,"accession_number":"0001193125-23-195289","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["1.01","1.02","2.01","7.01","8.01","9.01"],"status":"ready","headline":"Aeglea sells global rights to pegzilarginase to Immedica for $15M upfront + up to $100M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold pegzilarginase (for Arginase 1 Deficiency) to Immedica for $15M upfront and up to $100M in milestone payments.","Milestones contingent on European reimbursement decisions and FDA approval of pegzilarginase.","Prior license agreement between Aeglea and Immedica terminated in connection with the sale.","Proceeds net of expenses to be distributed to CVR holders from Spyre merger; first payments expected around Nov 14, 2023.","Marketing Authorisation Application for pegzilarginase under review by the European Medicines Agency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280350,"accession_number":"0001193125-23-187257","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aeglea BioTherapeutics transfers listing to Nasdaq Capital Market to address bid price deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice of Minimum Bid Price non-compliance on Jan 13, 2023; initial grace period ended July 12, 2023.","Nasdaq approved transfer to Capital Market effective July 14, 2023; stock symbol remains AGLE.","Granted additional 180-day grace period until Jan 8, 2024 to regain $1.00 bid price for 10 consecutive days.","Company intends to implement reverse stock split (approved by stockholders on June 6, 2023) to regain compliance.","Failure to regain compliance by Jan 8, 2024 could result in delisting; may appeal to Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298885,"accession_number":"0001193125-23-173242","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Aeglea BioTherapeutics completes acquisition of Spyre Therapeutics, raises $210M in PIPE financing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aeglea issued 13,013,636 common shares and 364,889 Series A Preferred shares to Spyre stockholders.","Company raised $210M via PIPE sale of 721,452 Series A Preferred shares to accredited investors.","Appointed Cameron Turtle as COO; Peter Harwin, Tomas Kiselak, and Michael Henderson as new directors.","Series A Preferred stock is non-voting, convertible into 1,000 common shares, subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-23T23:59:59+00:00|298885"}